Cargando…
Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers
PURPOSE: A subset of estrogen receptor–positive (ER-positive) breast cancer (BC) contains high levels of tumor-infiltrating lymphocytes (TILs), similar to triple-negative BC (TNBC). The majority of immuno-oncology trials target TNBCs because of the greater proportion of TIL-rich TNBCs. The extent to...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446500/ https://www.ncbi.nlm.nih.gov/pubmed/32923897 http://dx.doi.org/10.1200/PO.19.00350 |
_version_ | 1783574150663634944 |
---|---|
author | O’Meara, Tess Marczyk, Michal Qing, Tao Yaghoobi, Vesal Blenman, Kim Cole, Kimberly Pelekanou, Vasiliki Rimm, David L. Pusztai, Lajos |
author_facet | O’Meara, Tess Marczyk, Michal Qing, Tao Yaghoobi, Vesal Blenman, Kim Cole, Kimberly Pelekanou, Vasiliki Rimm, David L. Pusztai, Lajos |
author_sort | O’Meara, Tess |
collection | PubMed |
description | PURPOSE: A subset of estrogen receptor–positive (ER-positive) breast cancer (BC) contains high levels of tumor-infiltrating lymphocytes (TILs), similar to triple-negative BC (TNBC). The majority of immuno-oncology trials target TNBCs because of the greater proportion of TIL-rich TNBCs. The extent to which the immune microenvironments of immune-rich ER-positive BC and TNBC differ is unknown. PATIENTS AND METHODS: RNA sequencing data from The Cancer Genome Atlas (TCGA; n = 697 ER-positive BCs; n = 191 TNBCs) were used for discovery; microarray expression data from Molecular Taxonomy of Breast Cancer International Consortium (METABRIC; n = 1,186 ER-positive BCs; n = 297 TNBCs) was used for validation. Patients in the top 25th percentile of a previously published total TIL metagene score distribution were considered immune rich. We compared expression of immune cell markers, immune function metagenes, and immuno-oncology therapeutic targets among immune-rich subtypes. RESULTS: Relative fractions of resting mast cells (TCGA P(adj) = .009; METABRIC P(adj) = 4.09E-15), CD8(+) T cells (TCGA P(adj) = .015; METABRIC P(adj) = 0.390), and M2-like macrophages (TCGA P(adj)= 4.68E-05; METABRIC P(adj) = .435) were higher in immune-rich ER-positive BCs, but M0-like macrophages (TCGA P(adj) = 0.015; METABRIC P(adj) = .004) and M1-like macrophages (TCGA P(adj) = 9.39E-08; METABRIC P(adj) = 6.24E-11) were higher in immune-rich TNBCs. Ninety-one immune-related genes (eg, CXCL14, CSF3R, TGF-B3, LRRC32/GARP, TGFB-R2) and a transforming growth factor β (TGF-β) response metagene were significantly overexpressed in immune-rich ER-positive BCs, whereas 41 immune-related genes (eg, IFNG, PD-L1, CTLA4, MAGEA4) were overexpressed in immune-rich TNBCs in both discovery and validation data sets. TGF-β pathway member genes correlated negatively with expression of immune activation markers (IFNG, granzyme-B, perforin) and positively with M2-like macrophages (IL4, IL10, and MMP9) and regulatory T-cell (FOXP3) markers in both subtypes. CONCLUSION: Different immunotherapy strategies may be optimal in immune-rich ER-positive BC and TNBC. Drugs targeting the TGF-β pathway and M2-like macrophages are promising strategies in immune-rich ER-positive BCs to augment antitumor immunity. |
format | Online Article Text |
id | pubmed-7446500 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Society of Clinical Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-74465002020-09-30 Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers O’Meara, Tess Marczyk, Michal Qing, Tao Yaghoobi, Vesal Blenman, Kim Cole, Kimberly Pelekanou, Vasiliki Rimm, David L. Pusztai, Lajos JCO Precis Oncol Original Reports PURPOSE: A subset of estrogen receptor–positive (ER-positive) breast cancer (BC) contains high levels of tumor-infiltrating lymphocytes (TILs), similar to triple-negative BC (TNBC). The majority of immuno-oncology trials target TNBCs because of the greater proportion of TIL-rich TNBCs. The extent to which the immune microenvironments of immune-rich ER-positive BC and TNBC differ is unknown. PATIENTS AND METHODS: RNA sequencing data from The Cancer Genome Atlas (TCGA; n = 697 ER-positive BCs; n = 191 TNBCs) were used for discovery; microarray expression data from Molecular Taxonomy of Breast Cancer International Consortium (METABRIC; n = 1,186 ER-positive BCs; n = 297 TNBCs) was used for validation. Patients in the top 25th percentile of a previously published total TIL metagene score distribution were considered immune rich. We compared expression of immune cell markers, immune function metagenes, and immuno-oncology therapeutic targets among immune-rich subtypes. RESULTS: Relative fractions of resting mast cells (TCGA P(adj) = .009; METABRIC P(adj) = 4.09E-15), CD8(+) T cells (TCGA P(adj) = .015; METABRIC P(adj) = 0.390), and M2-like macrophages (TCGA P(adj)= 4.68E-05; METABRIC P(adj) = .435) were higher in immune-rich ER-positive BCs, but M0-like macrophages (TCGA P(adj) = 0.015; METABRIC P(adj) = .004) and M1-like macrophages (TCGA P(adj) = 9.39E-08; METABRIC P(adj) = 6.24E-11) were higher in immune-rich TNBCs. Ninety-one immune-related genes (eg, CXCL14, CSF3R, TGF-B3, LRRC32/GARP, TGFB-R2) and a transforming growth factor β (TGF-β) response metagene were significantly overexpressed in immune-rich ER-positive BCs, whereas 41 immune-related genes (eg, IFNG, PD-L1, CTLA4, MAGEA4) were overexpressed in immune-rich TNBCs in both discovery and validation data sets. TGF-β pathway member genes correlated negatively with expression of immune activation markers (IFNG, granzyme-B, perforin) and positively with M2-like macrophages (IL4, IL10, and MMP9) and regulatory T-cell (FOXP3) markers in both subtypes. CONCLUSION: Different immunotherapy strategies may be optimal in immune-rich ER-positive BC and TNBC. Drugs targeting the TGF-β pathway and M2-like macrophages are promising strategies in immune-rich ER-positive BCs to augment antitumor immunity. American Society of Clinical Oncology 2020-06-26 /pmc/articles/PMC7446500/ /pubmed/32923897 http://dx.doi.org/10.1200/PO.19.00350 Text en © 2020 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Original Reports O’Meara, Tess Marczyk, Michal Qing, Tao Yaghoobi, Vesal Blenman, Kim Cole, Kimberly Pelekanou, Vasiliki Rimm, David L. Pusztai, Lajos Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers |
title | Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers |
title_full | Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers |
title_fullStr | Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers |
title_full_unstemmed | Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers |
title_short | Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers |
title_sort | immunological differences between immune-rich estrogen receptor–positive and immune-rich triple-negative breast cancers |
topic | Original Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446500/ https://www.ncbi.nlm.nih.gov/pubmed/32923897 http://dx.doi.org/10.1200/PO.19.00350 |
work_keys_str_mv | AT omearatess immunologicaldifferencesbetweenimmunerichestrogenreceptorpositiveandimmunerichtriplenegativebreastcancers AT marczykmichal immunologicaldifferencesbetweenimmunerichestrogenreceptorpositiveandimmunerichtriplenegativebreastcancers AT qingtao immunologicaldifferencesbetweenimmunerichestrogenreceptorpositiveandimmunerichtriplenegativebreastcancers AT yaghoobivesal immunologicaldifferencesbetweenimmunerichestrogenreceptorpositiveandimmunerichtriplenegativebreastcancers AT blenmankim immunologicaldifferencesbetweenimmunerichestrogenreceptorpositiveandimmunerichtriplenegativebreastcancers AT colekimberly immunologicaldifferencesbetweenimmunerichestrogenreceptorpositiveandimmunerichtriplenegativebreastcancers AT pelekanouvasiliki immunologicaldifferencesbetweenimmunerichestrogenreceptorpositiveandimmunerichtriplenegativebreastcancers AT rimmdavidl immunologicaldifferencesbetweenimmunerichestrogenreceptorpositiveandimmunerichtriplenegativebreastcancers AT pusztailajos immunologicaldifferencesbetweenimmunerichestrogenreceptorpositiveandimmunerichtriplenegativebreastcancers |